Asieris Pharmaceuticals

Executive Summary

Asieris Pharmaceuticals is a private biopharmaceutical company focused on developing innovative therapies for genitourinary tumors and women's health, with a mission to preserve patients' dignity. The company's lead products include Vesique (APL-1202) for non-muscle invasive bladder cancer and Cevira (APL-1702) for cervical high-grade squamous intraepithelial lesions (HSIL). These assets target significant unmet medical needs and have the potential to become standard-of-care treatments. Asieris has established a strong leadership team and is advancing a robust pipeline that integrates diagnostics and therapeutics. The company is positioned to capitalize on upcoming regulatory and clinical milestones, which could drive value creation for stakeholders.

Upcoming Catalysts (preview)

• Q3 2026Regulatory decision for APL-1702 (Cevira) in China for cervical HSIL75% success
• Q3 2026Phase 3 data readout for APL-1202 (Vesique) in combination with BCG for NMIBC65% success
• TBDPotential partnership or licensing agreement for ex-China rights to APL-1202 or APL-170250% success